Rituximab prescription patterns and efficacy in the induction treatment of ANCA-Associated Vasculitis in a Belgian multicenter cohort

Chasseur, P; Blockmans, Daniel Engelbert; Frenckell, Christian Von; Nicolas, J-B; Regniers, C; Vandergheynst, F.

doi:10.1080/17843286.2019.1578041

Cited by 4 publications

(1 citation statement)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Considering the complications due to possible disease flares, treatment compliance is an important issue [5]. In our study, we aimed to evaluate the effect of COVID-19 and the quarantine period on disease activity and treatment compliance in patients with various systemic vasculitis, by applying a telephone survey to our patients who have been regularly followed up in our vasculitis clinic.…”

Section: Introductionmentioning

confidence: 99%

A single center survey study of systemic vasculitis and COVID-19 during the first months of pandemic

et al. 2021

View full text Add to dashboard Cite

A single center survey study of systemic vasculitis and COVID-19 during the first months of pandemic INTRODUCTION: COVID-19 pandemic created concerns among patients receiving immunosuppressive therapy. Frequency of COVID-19 and impact of lockdown on treatment compliance in patients with vasculitis are largely unknown.PATIENTS AND METHOD: Patients with ANCA-associated and large vessel vasculitis that have been followed-up in our clinic were contacted by phone and a questionnaire containing home isolation status, treatment adherence and history of COVID-19 between March 1st and June 30th, 2020 was applied. RESULTS: The survey was applied to 103 patients (F/M: 59/44, mean age: 53.2±12.5). Thirtythree (32%) patients didn't attend at least one appointment; 98(95.1%) noted that they spent 3 months in home isolation. Five patients (4.8%) received immunosuppressives irregularly and 3(2.9%) developed symptoms due to undertreatment. Four (3.9%) patients admitted to hospital with a suspicion of COVID-19, but none of them had positive PCR or suggestive findings by imaging. COVID-19 diagnosed in a patient with granulomatosis with polyangiitis during hospitalization for disease flare and she died despite treatment. DISCUSSION: Frequency of COVID-19 was low in patients with vasculitis in our single center cohort during the first months of pandemic. Although outpatient appointments were postponed in one-third of our patients, high compliance with treatment and isolation rules ensured patients with vasculitis overcome this period with minimal morbidity and mortality.

show abstract

Section: Introductionmentioning

confidence: 99%

A single center survey study of systemic vasculitis and COVID-19 during the first months of pandemic

et al. 2021

View full text Add to dashboard Cite

show abstract

Rituximab

2020

Reactions Weekly

View full text Add to dashboard Cite

Systematic literature review informing the 2022 update of the EULAR recommendations for the management of ANCA-associated vasculitis (AAV): part 1—treatment of granulomatosis with polyangiitis and microscopic polyangiitis

Schirmer¹,

Sánchez‐Álamo

Hellmich³

et al. 2023

RMD Open

View full text Add to dashboard Cite

ObjectiveTo summarise and update evidence to inform the 2022 update of the EULAR recommendations for the management of antineutrophil cytoplasm antibody-associated vasculitis (AAV).MethodsA systematic literature review (SLR) was performed to identify current evidence regarding treatment of AAV. PubMed, EMBASE and the Cochrane library were searched from 1 February 2015 to 25 February 2022. The evidence presented here is focused on the treatment of granulomatosis with polyangiitis and microscopic polyangiitis.Results3517 articles were screened and 175 assessed by full-text review. Ninety articles were included in the final evidence synthesis. Cyclophosphamide and rituximab (RTX) show similar efficacy for remission induction (level of evidence (LoE) 1a) but RTX is more effective in relapsing disease (LoE 1b). Glucocorticoid (GC) protocols with faster tapering result in similar remission rates but lower rates of serious infections (LoE 1b). Avacopan can be used to rapidly taper and replace GC (LoE 1b). Data on plasma exchange are inconsistent depending on the analysed trial populations but meta-analyses based on randomised controlled trials demonstrate a reduction of the risk of end-stage kidney disease at 1 year but not during long-term follow-up (LoE 1a). Use of RTX for maintenance of remission is associated with lower relapse rates compared with azathioprine (AZA, LoE 1b). Prolonged maintenance treatment results in lower relapse rates for both, AZA (LoE 1b) and RTX (LoE 1b).ConclusionThis SLR provides current evidence to inform the 2022 update of the EULAR recommendations for the management of AAV.

show abstract

Rituximab prescription patterns and efficacy in the induction treatment of ANCA-Associated Vasculitis in a Belgian multicenter cohort

Cited by 4 publications

References 21 publications

A single center survey study of systemic vasculitis and COVID-19 during the first months of pandemic

A single center survey study of systemic vasculitis and COVID-19 during the first months of pandemic

Rituximab

Systematic literature review informing the 2022 update of the EULAR recommendations for the management of ANCA-associated vasculitis (AAV): part 1—treatment of granulomatosis with polyangiitis and microscopic polyangiitis

Contact Info

Product

Resources

About